Abstract: The present invention concerns a belt (1), with a belt body (10) which extends substantially in a longitudinal direction and substantially comprises a flexible material, wherein at least one tensioning member (13), preferably a plurality of tensioning members (13), is at least substantially embedded in the belt body (10) in the longitudinal direction and at least substantially surrounded by the flexible material of the belt body (10), and with a coating (14) which is arranged directly on the belt body (10) from a drive side (11) of the belt (1), wherein the coating (14) comprises a fabric layer (14b). The belt (1) is characterized in that facing the belt body (10), the coating (14) has a first film (14a) which is arranged between the belt body (10) and the fabric layer (14b) and is designed to isolate the belt body from the fabric layer (14b).

Abstract: The present disclosure relates to systems and methods for bioinformatics and data processing. In particular, in a first aspect, the present disclosure relates to methods and systems for generating a personalized treatment guideline for a patient and for selecting a treatment for a patient. In another aspect, the present disclosure relates to methods and systems for selecting patients for a clinical trial of a treatment. The invention resolves cases in which patients have more than one “actionable” aberration by combining the patient-specific molecular information and the treatment-specific molecular information further with a clinico-molecular disease model, specifically a scoring of genes and/or proteins that represents several aspects of their involvement into the disease. In this way, treatments and patients can be prioritized that are most likely to impact or impacted by the disease mechanism, respectively.

Abstract: A belt for drive systems includes: an elastic and flame-retardant belt body made from a polymeric material and at least one flame retardant additive, the belt body having a cover layer as a belt back and a substructure which has a force transmission zone; and a tension member embedded in the belt body, wherein the belt body is partially or completely provided with a coating, which coating is single- or multi-layered.

Abstract: A method for treating a tension member in the production of a belt. The belt includes at least a belt body made of a polymer material having elastic properties, a cover layer as a belt backing, and a substructure having a force-transmission zone. The tension member has a ribbed design and is embedded in the belt body. The tension member is treated with an overall treatment mixture which forms a cross-linked polymer that on the one hand enters into a mechanical connection with the tension member and on the other hand forms an adhesive connection with the belt body.

Abstract: There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumour as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin.

Abstract: A belt for drive systems includes: an elastic and flame-retardant belt body made from a polymeric material and at least one flame retardant additive, the belt body having a cover layer as a belt back and a substructure which has a force transmission zone; and a tension member embedded in the belt body, wherein the belt body is partially or completely provided with a coating, which coating is single- or multi-layered.

Abstract: The present disclosure describes systems and methods for using patient-specific genomic information to optimize or de-risk therapy for the patient. A user may identify a medication for consideration for prescription to a patient, and a genetic variant of the patient affecting a first protein. An analyzer may identify a second medication targeting the first protein, and may retrieve adverse event data from an adverse event database for patients co-medicated with both the first medication and second medication. The analyzer may determine, based on rates of adverse events, the likelihood of an adverse event occurring through co-medication of the first medication and second medication. Based on the likelihood, and based on a correspondence or non-correspondence between a protein activation characteristic of the first medication and the effect of the genetic variant of the patient, the analyzer may indicate or contra-indicate the first medication for the patient.

Abstract: A method for fabricating a belt with upstream treatment of a tension member. The belt comprises a belt body made of a polymeric material having elastic properties, having a top ply as belt backing and a substructure having a force transmission zone, and a tension member embedded into the belt body. The tension member has been treated with crosslinked polymer; in an upstream stage of the belt fabrication method, voids in the tension member are filled at least partly with crosslinked polymer and the tension member is sealed with an envelope layer of crosslinked polymer, this being done, in a single treatment stage or in at least two treatment stages, by wetting of the tension member with an overall treatment mixture comprising at least one prepolymer, at least one crosslinker and at least one solvent or dispersion medium, and then drying of the treated tension member.

Abstract: The present disclosure is directed to systems and methods for identifying unknown drug targets via adverse event data. An analyzer receives an identification of a first drug having one or more unknown target proteins and identifies a second drug related to the first drug. The analyzer retrieves, from an adverse event database, a first side effect profile associated with the first drug, and a second side effect profile associated with the second drug. The analyzer generates a third side effect profile comprising a subset of the first side effect profile not shared by the second side effect profile, and identifies a third drug having a fourth side effect profile comprising the third side effect profile. The analyzer retrieves a list of one or more target proteins of the third drug not targeted by the second drug, and presents the retrieved list as potential target proteins of the first drug.

Abstract: A belt comprises at least a belt body made of a polymer material having elastic properties, the belt including a cover layer as a belt backing, a substructure having a force-transmission zone, and a tension member in a ribbed design embedded in the belt body. The tension member is prepared with a cross-linked polyurethane in such a way that the polyurethane fills at least part of the tension member cavities. The polyurethane filling material enters into a mechanical connection to the tension member on the one hand and an adhesive connection to the belt body on the other hand. The polyurethane filling material has a Shore A hardness that is 0.5 to 10 times harder than the Shore A hardness of the belt body. The belt body is preferably likewise made of cross-linked polyurethane, in particular using a carbon tension member.

Abstract: A method for fabricating a belt with upstream treatment of a tension member. The belt comprises a belt body made of a polymeric material having elastic properties, having a top ply as belt backing and a substructure having a force transmission zone, and a tension member embedded into the belt body. The tension member has been treated with crosslinked polymer; in an upstream stage of the belt fabrication method, voids in the tension member are filled at least partly with crosslinked polymer and the tension member is sealed with an envelope layer of crosslinked polymer, this being done, in a single treatment stage or in at least two treatment stages, by wetting of the tension member with an overall treatment mixture comprising at least one prepolymer, at least one crosslinker and at least one solvent or dispersion medium, and then drying of the treated tension member.

Abstract: The present disclosure describes systems and methods for predicting a likely side effect profile for even new, untested medications. A predicted side effect profile may be generated based on intersections of side effect profiles of other medications that affect the same or related molecular entities, such as the nearby target proteins, involve the same pathways, or are otherwise similarly related. To generate a predicted side effect profile for a new drug targeting a novel or previously un-targeted protein target, an analyzer may query an adverse event database for records pertaining to patients who have taken drugs or combinations of drugs that target or affect molecular entities in the vicinity of the novel target within a global molecular entity graph, and, in some embodiments, may retrieve a plurality of adverse event records and generate an intersection of side effects associated with related targets to predict likely side effects for the novel target.

Abstract: The present disclosure is directed to systems and methods for identifying unknown drug targets via adverse event data. An analyzer receives an identification of a first drug having one or more unknown target proteins and identifies a second drug related to the first drug. The analyzer retrieves, from an adverse event database, a first side effect profile associated with the first drug, and a second side effect profile associated with the second drug. The analyzer generates a third side effect profile comprising a subset of the first side effect profile not shared by the second side effect profile, and identifies a third drug having a fourth side effect profile comprising the third side effect profile. The analyzer retrieves a list of one or more target proteins of the third drug not targeted by the second drug, and presents the retrieved list as potential target proteins of the first drug.

Abstract: The present disclosure relates to systems and methods for bioinformatics and data processing. In particular, in a first aspect, the present disclosure relates to methods and systems for generating a personalized treatment guideline for a patient and for selecting a treatment for a patient. In another aspect, the present disclosure relates to methods and systems for selecting patients for a clinical trial of a treatment. The invention resolves cases in which patients have more than one “actionable” aberration by combining the patient-specific molecular information and the treatment-specific molecular information further with a clinico-molecular disease model, specifically a scoring of genes and/or proteins that represents several aspects of their involvement into the disease. In this way, treatments and patients can be prioritized that are most likely to impact or impacted by the disease mechanism, respectively.

Abstract: The present disclosure is directed to systems and methods for identifying unknown drug targets via adverse event data. An analyzer receives an identification of a first drug having one or more unknown target proteins and identifies a second drug related to the first drug. The analyzer retrieves, from an adverse event database, a first side effect profile associated with the first drug, and a second side effect profile associated with the second drug. The analyzer generates a third side effect profile including a subset of the first side effect profile not shared by the second side effect profile, and identifies a third drug having a fourth side effect profile including the third side effect profile. The analyzer retrieves a list of one or more target proteins of the third drug not targeted by the second drug, and presents the retrieved list as potential target proteins of the first drug.

Abstract: Systems and methods are described herein for the prioritization of possible treatment options based on biomarkers, such as (but not limited to) tumor and germline-based genomic variants. The system and methods may thereby identify patient and the status of a biomarker in the treatment options tailored to a patient, in particular to his/her clinical, molecular, and/or genetic condition. Furthermore, the system and method provides a means for prioritizing the possible treatment options based on the extraction and contextualization of clinical and molecular knowledge. The system gathers and/or accesses biomarker information and transforms the information into prioritized, clinically actionable options identified for a specific patient case.

Abstract: A belt for drive technology having a belt body made from two polymer materials (A) and (B) with elastic properties and including a top layer as the belt back and a substructure with a force transfer zone and a tension member embedded in the belt body. The first material (A) contains 15 to 50% w/w of at least one fire-resistant additive and is used everywhere in the belt body where high mechanical properties are not required and the second material (B) contains 5 to 35% w/w of at least one fire-resistant additive and is used in the are of the belt body that is subjected to the highest mechanical stresses. The belt is particularly used as a tractive element for hoisting technology.

Abstract: The present disclosure describes systems and methods for multivarlate analysis of adverse event data. According to a first aspect, patient-specific genomic Information is used to optimize or de-risk therapy for the patient. According to other aspects of the invention, unknown drug targets are identified via adverse event data. According to still other espects, a medication is identified to exclude from use for an indication or from a clinical trial of another medication. According to another aspect, a predicted side effect profile is generated for a medication targeting a novel target. According to still another aspect, combination therapies are identified via adverse event data. According to another aspect, molecular interactions between a plurality of molecular entities are displayed in an intuitive format. According to still another aspect, molecular entities responsible for adverse event differences between similar indications are identified.

Abstract: Systems and methods are described herein for disease knowledge modeling and clinical treatment decision support. Disease or indication information, including identification of biomolecular entities associated with the indication may be culled through data mining to create a knowledge model of the indication. In some embodiments, the knowledge model may comprise a network of associations between molecular entities, including drug targets and biomarkers, genes, pathways. The model is used for prioritizing treatment decisions, for treatments comprising one or more medications associated with one or more molecular entities in the model. The priority of a suggested treatment depends on at least one property of one or more medications of the suggested treatment.

Abstract: A device and a method for producing impregnated reinforcements, in particular for composite materials such as drive belts. The method for producing the reinforcements includes: introducing the reinforcement into an applicator device; introducing at least one substance for impregnating the reinforcement into the applicator device; and, embodying the impregnated reinforcement. The device comprises at least one applicator through which the reinforcement is guided and at least one intake for a substance for impregnation.